Tatjana Tallo

https://www.etis.ee/CV/Tatjana_Tallo/est
25.01.1966
659 3951
tatjana.tallo@tai.ee

Teenistuskäik

Töökohad ja ametid
2012–...   
Tervise Arengu Instituut, Vanemteadur (1,00)
1997–2011   
Tervise Arengu Instituut, Teadur (1,00)
01.01.1997–31.12.2003   
Eksperimentaalse ja Kliinilise MeditsiiniInstituudi viroloogia osakonna teadur
01.01.1995–31.12.1997   
Profülaktilise Meditsiini Instituut, viroloogia osakond, teadur
01.01.1994–31.12.1994   
Profülaktilise Meditsiini Instituut, viroloogia osakond, kõrgema haridusega laborant
01.01.1994–31.12.1995   
Profülaktilise Meditsiini Instituut, viroloogia osakond, nooremteadur
01.01.1987–31.12.1993   
NSVL MA Eksperimentaalse Patoloogia ja Teraapia Instituut,kõrgema haridusega laborant, Suhhumi, Gruusia
 
 
Haridustee
1982–1987   
M.V. Lomonossovi nim. Moskva Riiklik Ülikool, keemik
 
 
Teadusorganisatsiooniline ja -administratiivne tegevus
2010−...   
Eesti Teadusfondi projekti taotluse retsensent
2008−...   
Rootsi valitsuse rahastatavas VISBY programm: Correlates of the clinical course and outcome of HCV infection, Eesti-poolne koordinaator
1995−...   
Eesti Immunoloogide Seltsi liige
1995−...   
Euroopa Kliinilise Viroloogia Seltsi liige
2004−2008   
Täitja sihtfinantseeritavas teadusteemas "Eestis levivate loodusliku levikuga puukentsefaliidi- ja hantaviiruste ning A-, B- ja C-hepatiidiviiruste molekulaar-epidemioloogia ja geneetiline iseloomustus"
2004−2008   
Rootsi Karolinska Instituudi Mikrobioloogia ja Onkobioloogia Keskuse doktorant
2002−2003   
Täitja ETF grandis reg.nr. 4218
1999−2003   
Täitja sihtfinantseeritavas teadusteemas "Loodusliku levikuga viirused ja viirusnakkused Eestis: looduslikud ohualad, tekitajate molekulaarbioloogiline iseloomustus, levik, organismi immuunvastus"
1998−2009   
Eesti-poolne vastutav täitja Rootsi valitsuse rahastavas Balti mere piirkonna ühisprogrammis: Molecular epidemiology of viral hepatitis A, B ja C
1996−1998   
Täitja ETF grandis reg. nr. 1993

Kvalifikatsioon

Teaduskraadid
Tatjana Tallo, doktorikraad, 2008, (juh) Ljudmilla Priimägi; Valentina Tefanova; Helene Norder; Lars Magnius, Molecular epidemiology of hepatitis A, B and C in Estonia (A-, B- ja C-hepatiidi molekulaar-epidemioloogia Eestis), Karolinska Instituut, Stockholm, Rootsi.
Tatjana Tallo, magistrikraad (teaduskraad), 2006, (juh) Lars Magnius; Helene Norder; Ljudmilla Priimägi; Valentina Tefanova, Molecular epidemiology of hepatitis A, B and C in Estonia (Hepatiit A, -B ja -C molekulaarne epidemioloogia Eestis), Karolinska Institute, Stockholm, Rootsi.
Tatjana Tallo, magistrikraad, 1994, (juh) Romanova N, assymmetric reactions of 1-2-phenyl-ethyl-4-methylazetidinon-2, State University named by M.V. Lomonosov, Moscow, Russia.
 
 
Teaduspreemiad ja tunnustused
2004, Tatjana Tallo, 6th Nordic-Baltic Congress on Infectious Diseases Teadusliku Komitee diplom: Molecular epidemiology of hepatitis C in Estonia, Palanga, Leedu
2002, Tatjana Tallo, 5th Nordic-Baltic Congress on Infectious Diseases Teadusliku Komitee esimene auhind: Sequential changes in HAV genotype distribution in Estonia 1994 to 2001, St. Peterburg, Venemaa
1991, Tatjana Tallo, Leiutuste ja avastuste riiklik komitee, Autorite Tunnustus No 171241 Mus musculus hiirte kultiveeritavate hübriidrakkude tüvi - paavianide G-immuunoglobuliinide vastaste monoklonaalsete antikehade produtsent
 
 
Teadustöö põhisuunad
VALDKOND: 1. Bio- ja keskkonnateadused; 1.2. Mikrobioloogia; PÕHISUUND: Alates 1994.a-st - B- ja C-viirushepatiitide immunoepidemioloogilised omadused riskirühmades. Alates 1998.a-st Eestis levivate A-, B- ja C-hepatiidiviiruste molekulaarepidemioloogia ja geneetiline iseloomustus

Jooksvad projektid

Juhendamisel väitekirjad

Juhendatud väitekirjad

Publikatsioonid

Klass
Aasta
Publikatsioon
 
1.1.
2012
Brjalin, V; Salupere, R; Tallo, T; Kuznetsova, T; Priimägi, L; Tefanova, V. (2012). Efficasy of peginterferon alfa-2a and ribavirin combination therapy in treatment-naive Estonian patients with chronic hepatitis C. Central European Journal of Public Health, 20 (2), 150−155.
1.3.
2010
Brjalin, V; Salupere, R; Tallo, T; Priimägi, L; Tefanova, V. (2010). Kroonilise C-hepatiidi haigete viirusevastase ravi tulemused. Eesti Arst, 89 (3), 172−178.
1.2.
2009
Paat, G. ; Uusküla, A.; Tefanova, V.; Tallo, T.;Priimägi, L.;Ahi, K. (2009). The trends and risk factors for hepatitis B occurrence in Estonia. Central European Journal of Public Health, 17, 108−111.
5.2.
2009
Brjalin, V.; Tallo, T.; Priimägi, L.; Tefanova, V.; Salupere, R. (2009). Treatment results of Estonian naive patients with chronic HCV infection. Well-known infections - the hottest features of diagnostics and treatment - Book of Abstracts: 8th Nordic-Baltic congress on infectious diseases, Saint Petersburg, Russia, September 23-26. 17.
5.2.
2009
Tefanova, V.; Tallo, T.; Rüütel, K.; Reshetnjak, I.; Priimägi, L.; Uusküla, A. (2009). Active HBV infection in some Estonian risk groups. Book of abstracts: 8th Nordic-Baltic Congress on Infectious Diseases "Well-known infections - the hottest features of diagnostics and treatment", Saint Petersburg, Russia, September, 23-26. 71.
1.1.
2008
Golovljova, I.; Katargina, O.; Geller, J.; Tallo, T.; Mittzenkov, V.; Vene, S.; Nemirov, K.; Kutsenko, A.; Kilosanidze, G.; Vasilenko, V.; Plyusnin, A.; Lundkvist, A. (2008). Unique signature amino acid substitution in Baltic tick-borne encephalitis virus (TBEV) strains within the Siberian TBEV sybtype. International Journal of Medical Microbiology, 298S1 (44), 108−120.
1.1.
2008
Tallo, T; Tefanova, V; Priimägi, L; Schmidt, J; Katargina, O; Michailov, M; Mukomolov, S; Magnius, L; Norder, H. (2008). D2: major subgenotype of hepatitis B virus in Russia and the Baltic region. Journal of General Virology, 89, 1829−1839.
2.3.
2008
Tallo, Tatajana (2008). Molecular epidemiology of hepatitis A, B and C in Estonia. (Doktoritöö, Swedish Institute for Infectious Disease Control). Stockholm, Rootsi: Karolinska Institute.
5.1.
2008
Rüütel, K.; Priimägi, L.; Tefanova, V.; Tallo, T.; Talu, A.; Abel-Ollo, K.; Uusküla, A. (2008). HCV prevalence and risk factors among injecting drug users in Estonia. Journal of Clinical Virology, 44: Programme and abstracts of European Society for Clinical Virology(ESCV), Winter Meeting, Amsterdam, The Netherlands, January 7-10, 2009. S24. (Suppl. 1).
1.1.
2007
Tallo, T.; Norder, H.; Tefanova, V.; Krispin, T.; Schmidt, J.; Ilmoja, M.; Orgulas, K.; Pruunsild, K.; Priimägi, L.; Magnius, LO. (2007). Genetic characterization of hepatitis C virus strains in Estonia: fluctuations in the predominating subtype with time. Journal of Medical Virology, 79 (4), 374−382.
5.2.
2007
Tallo, T.; Tefanova, V.; Priimägi, L.; Michailov, M.; Norder, H.; Magnius, L. (2007). Additional criteria support the classification of HBV genotype D into subgenotypes. Programme and Abstracts: 3rd European Congress of Virology, Nürnberg, Germany, September 1-5. 97.
5.2.
2007
Tefanova, V.; Tallo, T.; Priimägi, L. (2007). Trends in the epidemiology of hepatitis A infection in Estonia. Programme and Abstracts: 3rd European Congress of Virology, Nürnberg, Germany, September 1-5. 206.
5.2.
2007
Priimägi, L.; Tefanova, V.; Tallo, T.; Rüütel, K. (2007). Emerging HIV infection in Estonia. Programme and Abstracts: 3rd European Congress of Virology, Nürnberg, Germany, September 1-5. 176.
1.2.
2006
Tefanova, V.; Tallo, T.; Kutsar, K.; Priimägi, L. (2006). Urgent action needed to stop spread of hepatitis B and C in Estonian drug users. Euro surveillance : European communicable disease bulletin., 11 (1), E060126.3.
3.1.
2006
Tallo, T.; Norder, H.; Tefanova, V.; Krispin, T.; Schmidt, J.; Ilmoja, M.; Orgulas, K.; Pruunsild, K.; Priimägi, L.; Magnius, L. (2006). Genetic chatracterization of hepatitis C virus strains from Estonia. Journal of Clinical Virology: 12th International Symposium on Viral Hepatitis and Liver Disease, Paris, July 1-5. S205.
5.1.
2006
Kalinin, O.; Jern, C.; Tallo, T.; Thcakharian, V.; Gusev, D.; Znoiko, O.; Isaguliants, M.; Mukomolov, S.; Norder, H.; Mgnius, L. (2006). Spread of the natural hepatitis C virus recombinant outside Russia. Journal of Clinical Virology: 12th International Symposium on Viral Hepatitis and Liver Disease, Paris, July 1-5.
5.2.
2006
Tallo, T.; Norder, H.; Tefanova, V.; Priimägi, L.; Magnius, L. (2006). Analysis of complete genome of hepatitis B virus isolates from Estonia and the former USSR. Abstracts: 7th Nordic-Baltic Congress on Infectious Diseases, Riga, Latvia, September 18-20. 27.
5.2.
2006
Tefanova, V.; Tallo, T.; Katargina, O.; Priimägi, L. (2006). Shift in seropidemiology of hepatitis A in Estonian population. Abstracts: 7th Nordic-Baltic Congress on Infectious Diseases,Riga, Latvia, September 18-20. 25.
1.2.
2005
Priimägi, L.; Tefanova, V.; Tallo, T.; Schmidt, E. (2005). The role of serum Th1 and Th2 cytokines in patients with chronic hepatitis B and C virus infection. Acta Medica Lituanica, 12 (3), 28−31.
1.2.
2005
Tefanova, V., Tallo, T., Kutsar, K., Priimägi, L. (2005). Current trends in the epidemiology of viral hepatitis B and C in Estonia. EpiNorth, 6 (3), 57−61.
3.2.
2005
Priimägi, L.; Tefanova, V.; Tallo, T. (2005). Emerging viral hepatitis B and C in Estonia. G. Berencsi, A.S. Khan, J. Haloužka. Emerging Biological Threat (20−25).. Amsterdam ; Washington, DC: IOS Press. (NATO Science Series. Series I, Life and behavioural sciences; 370).
1.1.
2004
Tallo, T.; Norder, H.; Tefanova, V.; Krispin, T.; Priimagi, L.; Mukomolov, S.; Mikhailov, M.; Magnius, LO. (2004). Hepatitis B virus genotype D strains from Estonia share sequence similarity with strains from Siberia and may specify ayw4. Journal of Medical Virology, 74 (2), 221−227.
1.3.
2004
Tefanova, V.; Tallo, T.; Jaroslavtsev, N.; Kikoš, G.; Krupskaja, L.; Lisitsina, S.; Kutsar, K.; Priimägi, L. (2004). B- ja C-viirushepatiidid - aktuaalne epidemioloogiline probleem Eestis viimasel aastakümnel. Eesti Arst, 83 (3), 738−743.
1.1.
2003
Tallo, T.; Norder, H.; Tefanova, V.; Ott, K.; Ustina, V.; Prukk, T.; Solomonova, O.; Schmidt, J.; Zilmer, K.; Priimagi, L.; Krispin, T.; Magnius, L.O. (2003). Sequential changes in hepatitis A virus genotype distribution in Estonia during 1994 to 2001. Journal of Medical Virology, 70 (2), 187−193.
1.2.
2003
Priimiagi LS, Tefanova VT, Tallo TG, Shmidt EV, Solomonova OV, Tuisk TP. (2003). Immune-regulating Th1- and Th2-cytokines in chronic infections caused by hepatitis B and C viruses. Voprosy Virusologii, 48 (4), 37−40.
1.3.
2003
Tefanova, V.; Priimägi, L.; Tallo, T.; Jaroslavtsev, N. (2003). Hepatitis B and C infection among intravenous drug users in prisons and visitors of anonymous consulting rooms in Estonia: prevalence and risk factors. Connections, 14, 8−9.
1.2.
2002
Tefanova VT, Tallo TG, Priimiagi LS, Kikosh GV, Krupskaia LM, Lisitsyna SA, Noorlind IuP. (2002). Hepatitis A in Estonia (1990-1999). Zhurnal Mikrobiologii, Epidemiologii i Immunologii, 2, 22−26.
1.2.
2002
Priimiagi LS, Tefanova VT, Tallo TG, Shmidt EV, Solomonova OV, Tuisk TP, Kikosh GV, Krupskaia LM, Lisitsyna SA. (2002). Th1-cytokines in chronic hepatitis B and C. Voprosy Virusologii, 47 (3), 23−27.
1.2.
2001
Tefanova VT, Priimiagi LS, Tallo TG (2001). Functional and metabolic activity of peripheral blood neutrophiles in acute viral hepatitis B and C. Zhurnal Mikrobiologii, Epidemiologii i Immunologii, 1, 43−47.
1.1.
2000
Tallo T, Lappalainen M, Tefanova V, Priimagi I (2000). Distribution of hepatitis C virus genotypes in patients with chronic hepatitis C in Northern Estonia. Acta Virologica, 44, 175−178.
1.2.
1999
Tefanova VT, Tallo TG, Priimägi LS, Kikosh GV, Krupskaia LM. (1999). The epidemiological aspects of viral hepatitides in Estonia. Zhurnal Mikrobiologii, Epidemiologii i Immunologii, 2, 39−42.
1.2.
1999
Priimiagi LS, Kremerman IB, Tefanov VT, Tallo TG, Osadchaia GS (1999). Functional status of the interferon system in inapparent and clinical infection with hepatitis B and C viruses. Voprosy Virusologii, 44 (2), 85−88.
1.2.
1999
Priimiagi LS, Kremerman IB, Tallo TG, Tefanova VT, Luman MG, Osadchaia GS. (1999). Interferon system status in hemodialysis patients infected with hepatitis B and C viruses. Voprosy Virusologii, 44 (4), 167−169.
25.04.2019

Tatjana Tallo

https://www.etis.ee/CV/Tatjana_Tallo/eng
25.01.1966
659 3951
tatjana.tallo@tai.ee

Career

Institution(s) and position(s)
2012–...   
National Institute for Health Development, Senior Researcher (1,00)
1997–2011   
National Institute for Health Development, Researcher (1,00)
01.01.1997–31.12.2003   
Estonian Institute of Experimental and Clinical Medicine, Tallinn, Estonia, Researcher
01.01.1995–31.12.1997   
Institute of Preventive Medicine, group of immunodiagnistic of viral hepatitis, Tallinn, Estonia, Researcher
01.01.1994–31.12.1994   
Institute of Preventive Medicine, group of immunodiagnistic of viral hepatitis, Tallinn, Estonia, technician
01.01.1994–31.12.1995   
Institute of Preventive Medicine, group of immunodiagnistic of viral hepatitis, Tallinn, Estonia, Junior Researcher
01.01.1987–31.12.1993   
Institute of Experimental Pathology and Therapy, Acad.Med. Sci., Immunotechnology Department, Georgia, Sukhumi, technician
 
 
Education
1982–1987   
Basic University degree in Chemistry, Moscow State University named by M.V. Lomonosov, Moscow, Russia
 
 
R&D related managerial and administrative work
2010−...   
Referee of grant applications of Estonian Science Foundation
2008−...   
VISBY program funded by Swedish Institute: Correlates of the clinical course and outcome of HCV infection, coordinator of project in Estonia
1995−...   
The member of Estonian Society for Immunology
1995−...   
The member of European Society for Clinical Virology
2004−2008   
PhD student at Microbiology and Tumor Biology Center, Karolonska Institute, Stockholm, Sweden
2002−2003   
Co-applicant for grant reg. nr.4218 from Estonian Scientific Foundation
1999−2003   
Co-applicant in project "Viral zoonoses and zoonotic viruses in Estonia: endemic areas, molecular-biological characteristics, distribution and immune reponse", from Estonian Ministry of Education and Science
1998−2009   
Estonian counterpart in program for Baltic countries: Molecular epidemiology of Viral Hepatitis A, B and C
1996−1998   
Co-applicant for grant reg. nr. 1993 from Estonian Scientific Foundation

Qualifications

Academic degrees
Tatjana Tallo, Doctor's Degree, 2008, (sup) Ljudmilla Priimägi; Valentina Tefanova; Helene Norder; Lars Magnius, Molecular epidemiology of hepatitis A, B and C in Estonia, Karolinska Institute, Stockholm, Sweden.
Tatjana Tallo, Master's Degree, 2006, (sup) Lars Magnius; Helene Norder; Ljudmilla Priimägi; Valentina Tefanova, Molecular epidemiology of hepatitis A, B and C in Estonia, Karolinska Institute, Stockholm, Sweden.
Tatjana Tallo, Master's Diploma, 1994, (sup) Romanova N, assymmetric reactions of 1-2-phenyl-ethyl-4-methylazetidinon-2 (assymmetric reactions of 1-2-phenyl-ethyl-4-methylazetidinon-2), State University named by M.V. Lomonosov, Moscow, Russia.
 
 
Honours & awards
2004, Tatjana Tallo, 6th Nordic-Baltic Congress of Infectious Diseases, Palanga, Lithuania, Scientific Committee diploma for the best presentation
2002, Tatjana Tallo, 5th Nordic-Baltic Congress of Infectious Diseases, St. Petersburg, Russia, Scientific Committee award for the best presentation
1991, Tatjana Tallo, The State Committee on Inventions and Discoveries at the State Committee of the USSR on Science and Techniques. Author’s Certificate No. 1712411
 
 
Field of research
FIELD OF RESEARCH: 1. Biosciences and Environment; 1.2. Microbiology; SPECIALITY: The study on immunoepidemiology of hepatitis B and C viruses in groups of incresed risk in Estonia (from 1994). The study on genetic characteristics and molecular epidemiology of hepatitis A, B and C viruses (from 1998).
 
 

Projects in progress

Dissertations under supervision

Supervised dissertations

Publications

Category
Year
Publication
 
1.1.
2012
Brjalin, V; Salupere, R; Tallo, T; Kuznetsova, T; Priimägi, L; Tefanova, V. (2012). Efficasy of peginterferon alfa-2a and ribavirin combination therapy in treatment-naive Estonian patients with chronic hepatitis C. Central European Journal of Public Health, 20 (2), 150−155.
1.3.
2010
Brjalin, V; Salupere, R; Tallo, T; Priimägi, L; Tefanova, V. (2010). Kroonilise C-hepatiidi haigete viirusevastase ravi tulemused. Eesti Arst, 89 (3), 172−178.
1.2.
2009
Paat, G. ; Uusküla, A.; Tefanova, V.; Tallo, T.;Priimägi, L.;Ahi, K. (2009). The trends and risk factors for hepatitis B occurrence in Estonia. Central European Journal of Public Health, 17, 108−111.
5.2.
2009
Brjalin, V.; Tallo, T.; Priimägi, L.; Tefanova, V.; Salupere, R. (2009). Treatment results of Estonian naive patients with chronic HCV infection. Well-known infections - the hottest features of diagnostics and treatment - Book of Abstracts: 8th Nordic-Baltic congress on infectious diseases, Saint Petersburg, Russia, September 23-26. 17.
5.2.
2009
Tefanova, V.; Tallo, T.; Rüütel, K.; Reshetnjak, I.; Priimägi, L.; Uusküla, A. (2009). Active HBV infection in some Estonian risk groups. Book of abstracts: 8th Nordic-Baltic Congress on Infectious Diseases "Well-known infections - the hottest features of diagnostics and treatment", Saint Petersburg, Russia, September, 23-26. 71.
1.1.
2008
Golovljova, I.; Katargina, O.; Geller, J.; Tallo, T.; Mittzenkov, V.; Vene, S.; Nemirov, K.; Kutsenko, A.; Kilosanidze, G.; Vasilenko, V.; Plyusnin, A.; Lundkvist, A. (2008). Unique signature amino acid substitution in Baltic tick-borne encephalitis virus (TBEV) strains within the Siberian TBEV sybtype. International Journal of Medical Microbiology, 298S1 (44), 108−120.
1.1.
2008
Tallo, T; Tefanova, V; Priimägi, L; Schmidt, J; Katargina, O; Michailov, M; Mukomolov, S; Magnius, L; Norder, H. (2008). D2: major subgenotype of hepatitis B virus in Russia and the Baltic region. Journal of General Virology, 89, 1829−1839.
2.3.
2008
Tallo, Tatajana (2008). Molecular epidemiology of hepatitis A, B and C in Estonia. (Doktoritöö, Swedish Institute for Infectious Disease Control). Stockholm, Rootsi: Karolinska Institute.
5.1.
2008
Rüütel, K.; Priimägi, L.; Tefanova, V.; Tallo, T.; Talu, A.; Abel-Ollo, K.; Uusküla, A. (2008). HCV prevalence and risk factors among injecting drug users in Estonia. Journal of Clinical Virology, 44: Programme and abstracts of European Society for Clinical Virology(ESCV), Winter Meeting, Amsterdam, The Netherlands, January 7-10, 2009. S24. (Suppl. 1).
1.1.
2007
Tallo, T.; Norder, H.; Tefanova, V.; Krispin, T.; Schmidt, J.; Ilmoja, M.; Orgulas, K.; Pruunsild, K.; Priimägi, L.; Magnius, LO. (2007). Genetic characterization of hepatitis C virus strains in Estonia: fluctuations in the predominating subtype with time. Journal of Medical Virology, 79 (4), 374−382.
5.2.
2007
Tallo, T.; Tefanova, V.; Priimägi, L.; Michailov, M.; Norder, H.; Magnius, L. (2007). Additional criteria support the classification of HBV genotype D into subgenotypes. Programme and Abstracts: 3rd European Congress of Virology, Nürnberg, Germany, September 1-5. 97.
5.2.
2007
Tefanova, V.; Tallo, T.; Priimägi, L. (2007). Trends in the epidemiology of hepatitis A infection in Estonia. Programme and Abstracts: 3rd European Congress of Virology, Nürnberg, Germany, September 1-5. 206.
5.2.
2007
Priimägi, L.; Tefanova, V.; Tallo, T.; Rüütel, K. (2007). Emerging HIV infection in Estonia. Programme and Abstracts: 3rd European Congress of Virology, Nürnberg, Germany, September 1-5. 176.
1.2.
2006
Tefanova, V.; Tallo, T.; Kutsar, K.; Priimägi, L. (2006). Urgent action needed to stop spread of hepatitis B and C in Estonian drug users. Euro surveillance : European communicable disease bulletin., 11 (1), E060126.3.
3.1.
2006
Tallo, T.; Norder, H.; Tefanova, V.; Krispin, T.; Schmidt, J.; Ilmoja, M.; Orgulas, K.; Pruunsild, K.; Priimägi, L.; Magnius, L. (2006). Genetic chatracterization of hepatitis C virus strains from Estonia. Journal of Clinical Virology: 12th International Symposium on Viral Hepatitis and Liver Disease, Paris, July 1-5. S205.
5.1.
2006
Kalinin, O.; Jern, C.; Tallo, T.; Thcakharian, V.; Gusev, D.; Znoiko, O.; Isaguliants, M.; Mukomolov, S.; Norder, H.; Mgnius, L. (2006). Spread of the natural hepatitis C virus recombinant outside Russia. Journal of Clinical Virology: 12th International Symposium on Viral Hepatitis and Liver Disease, Paris, July 1-5.
5.2.
2006
Tallo, T.; Norder, H.; Tefanova, V.; Priimägi, L.; Magnius, L. (2006). Analysis of complete genome of hepatitis B virus isolates from Estonia and the former USSR. Abstracts: 7th Nordic-Baltic Congress on Infectious Diseases, Riga, Latvia, September 18-20. 27.
5.2.
2006
Tefanova, V.; Tallo, T.; Katargina, O.; Priimägi, L. (2006). Shift in seropidemiology of hepatitis A in Estonian population. Abstracts: 7th Nordic-Baltic Congress on Infectious Diseases,Riga, Latvia, September 18-20. 25.
1.2.
2005
Priimägi, L.; Tefanova, V.; Tallo, T.; Schmidt, E. (2005). The role of serum Th1 and Th2 cytokines in patients with chronic hepatitis B and C virus infection. Acta Medica Lituanica, 12 (3), 28−31.
1.2.
2005
Tefanova, V., Tallo, T., Kutsar, K., Priimägi, L. (2005). Current trends in the epidemiology of viral hepatitis B and C in Estonia. EpiNorth, 6 (3), 57−61.
3.2.
2005
Priimägi, L.; Tefanova, V.; Tallo, T. (2005). Emerging viral hepatitis B and C in Estonia. G. Berencsi, A.S. Khan, J. Haloužka. Emerging Biological Threat (20−25).. Amsterdam ; Washington, DC: IOS Press. (NATO Science Series. Series I, Life and behavioural sciences; 370).
1.1.
2004
Tallo, T.; Norder, H.; Tefanova, V.; Krispin, T.; Priimagi, L.; Mukomolov, S.; Mikhailov, M.; Magnius, LO. (2004). Hepatitis B virus genotype D strains from Estonia share sequence similarity with strains from Siberia and may specify ayw4. Journal of Medical Virology, 74 (2), 221−227.
1.3.
2004
Tefanova, V.; Tallo, T.; Jaroslavtsev, N.; Kikoš, G.; Krupskaja, L.; Lisitsina, S.; Kutsar, K.; Priimägi, L. (2004). B- ja C-viirushepatiidid - aktuaalne epidemioloogiline probleem Eestis viimasel aastakümnel. Eesti Arst, 83 (3), 738−743.
1.1.
2003
Tallo, T.; Norder, H.; Tefanova, V.; Ott, K.; Ustina, V.; Prukk, T.; Solomonova, O.; Schmidt, J.; Zilmer, K.; Priimagi, L.; Krispin, T.; Magnius, L.O. (2003). Sequential changes in hepatitis A virus genotype distribution in Estonia during 1994 to 2001. Journal of Medical Virology, 70 (2), 187−193.
1.2.
2003
Priimiagi LS, Tefanova VT, Tallo TG, Shmidt EV, Solomonova OV, Tuisk TP. (2003). Immune-regulating Th1- and Th2-cytokines in chronic infections caused by hepatitis B and C viruses. Voprosy Virusologii, 48 (4), 37−40.
1.3.
2003
Tefanova, V.; Priimägi, L.; Tallo, T.; Jaroslavtsev, N. (2003). Hepatitis B and C infection among intravenous drug users in prisons and visitors of anonymous consulting rooms in Estonia: prevalence and risk factors. Connections, 14, 8−9.
1.2.
2002
Tefanova VT, Tallo TG, Priimiagi LS, Kikosh GV, Krupskaia LM, Lisitsyna SA, Noorlind IuP. (2002). Hepatitis A in Estonia (1990-1999). Zhurnal Mikrobiologii, Epidemiologii i Immunologii, 2, 22−26.
1.2.
2002
Priimiagi LS, Tefanova VT, Tallo TG, Shmidt EV, Solomonova OV, Tuisk TP, Kikosh GV, Krupskaia LM, Lisitsyna SA. (2002). Th1-cytokines in chronic hepatitis B and C. Voprosy Virusologii, 47 (3), 23−27.
1.2.
2001
Tefanova VT, Priimiagi LS, Tallo TG (2001). Functional and metabolic activity of peripheral blood neutrophiles in acute viral hepatitis B and C. Zhurnal Mikrobiologii, Epidemiologii i Immunologii, 1, 43−47.
1.1.
2000
Tallo T, Lappalainen M, Tefanova V, Priimagi I (2000). Distribution of hepatitis C virus genotypes in patients with chronic hepatitis C in Northern Estonia. Acta Virologica, 44, 175−178.
1.2.
1999
Tefanova VT, Tallo TG, Priimägi LS, Kikosh GV, Krupskaia LM. (1999). The epidemiological aspects of viral hepatitides in Estonia. Zhurnal Mikrobiologii, Epidemiologii i Immunologii, 2, 39−42.
1.2.
1999
Priimiagi LS, Kremerman IB, Tefanov VT, Tallo TG, Osadchaia GS (1999). Functional status of the interferon system in inapparent and clinical infection with hepatitis B and C viruses. Voprosy Virusologii, 44 (2), 85−88.
1.2.
1999
Priimiagi LS, Kremerman IB, Tallo TG, Tefanova VT, Luman MG, Osadchaia GS. (1999). Interferon system status in hemodialysis patients infected with hepatitis B and C viruses. Voprosy Virusologii, 44 (4), 167−169.
25.04.2019
Detailne otsing
  • Leitud 7 kirjet
ProgrammLiikNumberNimiProjekti algusProjekti lõppVastutav täitjaAsutusFinantseerijapoolne rahastamine
ETFETF7650Eesti C-hepatiidiviiruse isolaatide geneetiline varieeruvus ja viirusevastase ravi tulemus kroonilistel hepatiidihaigetel01.01.200831.12.2011Valentina TefanovaTervise Arengu Instituut59 514,48 EUR
SFSF0942657s04EESTIS LEVIVATE LOODUSLIKU LEVIKUGA PUUKENTSEFALIIDI- JA HANTAVIIRUSTE NING A-, B- JA C-HEPATIIDIVIIRUSTE MOLEKULAAR-EPIDEMIOLOOGIA JA GENEETILINE ISELOOMUSTUS01.01.200431.12.2008Ljudmilla PriimägiTervise Arengu Instituut304 219,46 EUR
SFSF0940033s09Emergeeruvate zoonooside tekitajad ja hepatotroopsed viirused Eestis: olemasolu, levik, kooseksisteerimine, geneetiline iseloomustus, tähendus inimese haigestumisele.01.01.200931.12.2014Irina GolovljovaTervise Arengu Instituut503 733,24 EUR
MUUVIR.HIV-HEPHIV-i ja hepatiidi levimus, riskikäitumine, teadmised ja hoiakud Eesti vanglates.01.07.200631.01.2008Ljudmilla PriimägiTervise Arengu Instituut154 451,25 EUR
ETFETF5961Molekulaar-epidemioloogiline uuring Eestis isoleeritud B-hepatiidiviiruse genotüüpide leviku ja kliinilise tähtsuse väljaselgitamiseks01.01.200431.12.2007Ljudmilla PriimägiTervise Arengu Instituut29 612,90 EUR
ETFETF6938Puukidega ülekantavate haigustekitajate (Puukentsefaliidiviirus, Borrelia, Anaplasma ja Babesia) tsirkulatsioon Eestis: nende levik, kooseksisteerimine ja geneetiline iseloomustus01.01.200731.12.2010Irina GolovljovaTervise Arengu Instituut63 134,50 EUR
ETFETF8691Selgroogsete liikide kompetentsus puukidega ülekantavate haigustekitajate säilitamisel ja ülekandmisel looduslikes kolletes Eestis ning kohalike Borrelia liikide geneetiline iseloomustus.01.01.201131.12.2014Irina GolovljovaTervise Arengu Instituut48 000,00 EUR